Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gepirone. Organon.

R A Leslie1

  • 1Addenbrooke's Centre for Clinical Investigation, Cambridge, UK. Ron_Leslie-1@gsk.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
PubMed
Summary
This summary is machine-generated.

Gepirone, a novel antidepressant, selectively targets serotonin 5-HT1A receptors. Further research is needed to fully understand its pre- and post-synaptic actions for therapeutic efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evolving the EN 1500 test method for alcohol-based hand rub closer to clinical reality by reducing the organic load on hands and enabling product to be applied to dry hands.

The Journal of hospital infection·2023
Same author

Efficacy of alcohol-based hand sanitizers against human norovirus using RNase-RT-qPCR with validation by human intestinal enteroid replication.

Letters in applied microbiology·2020
Same author

Lateralized microstructural changes in early-stage Parkinson's disease in anterior olfactory structures, but not in substantia nigra.

Journal of neurology·2017
Same author

Management of arterial lines and blood sampling in intensive care: a threat to patient safety.

Anaesthesia·2013
Same author

Autoradiographic localization of 5-HT(3) receptor ligand binding in the cat brainstem.

Neurochemistry international·2010
Same author

Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postrema, and dorsal motor nucleus of the vagus.

Neurochemistry international·2010
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Drug Development

Background:

  • Gepirone is a pyridinyl piperazine 5-HT1A receptor agonist developed as an antidepressant.
  • Development involved multiple pharmaceutical companies, including Fabre-Kramer, Bristol-Myers Squibb, and NV Organon.
  • Regulatory submissions and market launch expectations were established for the US and Europe.

Purpose of the Study:

  • To investigate the mechanism of action of gepirone.
  • To compare the receptor selectivity of gepirone with buspirone.
  • To explore the differential effects of gepirone on pre- and post-synaptic 5-HT1A receptors.

Main Methods:

  • Mechanism of action studies.
  • Comparative receptor binding assays.

Related Experiment Videos

  • Long-term in vivo studies.

    • Main Results:

    • Gepirone exhibits significantly higher selectivity for 5-HT1A receptors compared to dopamine D2 receptors than buspirone.
    • Gepirone acts as an agonist at presynaptic 5-HT1A receptors and a partial agonist at post-synaptic 5-HT1A receptors.
    • Peak sales projections for gepirone reached Euro 300 million.

    Conclusions:

    • Gepirone's distinct pre- and post-synaptic activity at 5-HT1A receptors warrants further investigation.
    • Understanding the contribution of these receptor subtypes is crucial for elucidating gepirone's therapeutic effects.
    • Gepirone represents a promising compound in antidepressant development with significant market potential.